143 results about "Butyrylcholinesterase" patented technology

The present invention provides methods for the large-scale production of recombinant butyrylcholinesterase fused to human serum albumin in cell culture, and in the milk and/or urine of transgenic mammals. The recombinant butyrylcholinesterase-albumin fusion protein of this invention can be used to treat and/or prevent organophosphate pesticide poisoning, nerve gas poisoning, cocaine intoxication, and succinylcholine-induced apnea.

The invention provides a butyrylcholinesterase variant having the amino acid sequence selected from SEQ ID NOS: 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof. In addition, the invention provides a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant selected from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof, under conditions that allow conversion of a camptothecin derivative to a topoisomerase inhibitor. Further, the invention provides a method of treating cancer by administering to an individual an effective amount of a butyrylcholinesterase variant selected from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof, exhibiting increased capability to convert a camptothecin derivative to a topoisomerase inhibitor compared to butyrylcholinesterase.

Disclosed are detoxifying enzyme conjugates, including conjugates of variants of such detoxifying enzymes. The detoxifying enzymes are preferably chlolinesterases, and more preferably, butyrylcholinesterase. Also disclosed are methods of making and using such conjugates.

The invention provides a butyrylchinesterase variant, a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant and a method of treating cancer by administering to an individual an effective amount a butyrylcholinesterase variant exhibiting increased capability to convert a camptothecin derivative to a topoisomerase inhibitor compared to butyrylcholinesterase.

The present invention concerns the production of human butyrylcholinesterase (BuChE) in transgenic plants and use of the derived BuChE as effective countermeasures against toxic agents such as pesticides, toxins, certain drugs and non-conventional warfare agents, as well as treatments for diseases and conditions associated with depressed cholinesterase levels.

A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, and A199S/F227A/S287G/A328W/E441D all have enhanced catalytic efficiency for (−)-cocaine compared with wild-type BChE.

The invention relates to the preparation of a polyphenol oxidase biosensor, which is prepared by adopting carbon nanosphere embedded polyphenol oxidase modified glassy carbon electrode and used for detecting pesticide residues. Polyphenol oxidase is a class of metalloproteinases with wide sources, compared with acetylcholinesterase, butyrylcholinesterase and organophosphorus hydrolase and the like, the polyphenol oxidase has the advantages of wide sources, low price and the like. According to the invention, carbon nanosphere is adopted to embed polyphenol oxidase, and has good biocompatibility, higher mechanical strength and larger specific surface area, so that the fixed quantity of an electrode surface enzyme is improved, and the biological activity of the polyphenol oxidase is maintained to the maximum degree. Therefore, the biological catalytic efficiency of the enzyme, and analysis and detection performance of the biosensor are improved. The polyphenol oxidase biosensor prepared through the method has lower detection limit and an excellent linear range to glyphosate, and has excellent recovery rate to sample detection, meanwhile, has excellent repeatability, reproducibility and stability, and can be used for detecting pesticide residues.

The present invention discloses a trifluoromethyl containing quinazoline derivative and a preparation method and application thereof. The preparation method comprises the following steps of: under the condition that copper and ligand exist, an N-cyano substituted aryl carboxamides compound reacting with a togni reagent in a solvent, and after completion of the reaction, obtaining the trifluoromethyl containing quinazoline derivative after treatment. The reaction substrate is readily available, the operation is convenient, the obtained quinazolinone derivative is of rich diversity, the required reaction condition is mild, and the reaction time is short. The all-in-one-pot reaction is realized, and not only a structural mother kernel of quinazoline is obtained, but also trifluoromethyl is introduced into the mother kernel structure. And the quinazolinone compound contains the spiropyran compound can be synthesized, which cannot be achieved by the prior art. The obtained product has good activity in inhibiting enzyme acetylcholinesterase and butyrylcholinesterase.

The invention discloses multiple-target effects of an isoflavone derivative and its application in improvement of learning and memory. Specifically, the invention discloses that a compound J39136 has the effects of: upregulating the expression of SIRT1 protein with damage repair and neuroprotective effects; inhibiting the activity of acetylcholinesterase and butyrylcholinesterase, and dose-dependently inhibiting the acetylcholinesterase activity of cells under a safe dose; protecting nerve cells, inhibiting abnormal expression of beta-APP, and reducing Abeta1-42 secretion; and regulating neuroinflammation. Animal experimental results prove that J39136 has low toxicity, can penetrate the blood-brain barrier, and can significantly improve scopolamine caused mouse dementia and strengthen learning and memory functions. Preclinical study results prompt that J39136 is expected to become the drug for prevention and/or treatment of learning and memory disorder and Alzheimer's disease.

The invention belongs to the technical field of medicine and particularly relates to flavonoid compounds separated from millettia pachycarpa as a leguminous plant and having AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) inhibiting activity, pharmaceutical salts of the flavonoid compounds and pharmaceutical composition containing the compounds. The three flavonoid compounds have a remarkable inhibiting effect on AChE and BuChE and show unique advantages in preventing and treating learning and memory disorder and senile dementia diseases.

The invention relates to 4-amino alkoxy-3-methoxy cinnamic acid benzamide compounds as well as preparation methods and applications thereof. The preparation methods of the compounds comprise the following steps: step 1, ferulic acid is taken as a starting material and subjected to a reaction with substituted aniline under the conditions of a first solvent and a condensing agent, and corresponding ferulic acid benzamide compounds are obtained; step 2, the ferulic acid benzamide compounds are subjected to a reaction with a dihalogenated alkyl compound under the condition of a second solvent and a first alkaline condition, and a corresponding halogen compounds are obtained; step 3, the halogen compounds are subjected to a reaction with an organic amine compound under the condition of a third solvent, and the 4-amino alkoxy-3-methoxy cinnamic acid benzamide compounds are obtained. The compounds have a remarkable inhibiting effect on acetylcholinesterase, the IC50 is 0.01 mu M-5 mu M, and the inhibitory activity on acetylcholinesterase is greatly higher than that on butyrylcholinesterase, so that the compounds have certain selective inhibiting effect on acetylcholinesterase.

The invention provides a vegetable pesticide residue detection method, and particularly relates to the technical field of pesticide residue detection. The method comprises the following steps of S1, performing reagent preparation: preparing a buffer solution, a butyrylcholinesterase solution, a substrate and a color developing agent; S2, performing sample preparation: cutting leaves, melon pulp orthe like into small blocks, putting the small blocks into an extraction bottle, adding the buffer solution, shaking to obtain an extracting solution, and standing to obtain a supernate for later use;S3, performing control solution detection: adding the buffer solution and the butyrylcholinesterase solution into a reaction flask, adding the color developing agent, performing placement for a certain time in a constant-temperature incubator, adding the substrate, pouring a mixture into a cuvette, and carrying out detection by using a pesticide residue fast detection instrument; S4, performing to-be-detected sample solution detection: taking the supernate, the butyrylcholinesterase solution and the color developing agent, performing placement in the constant-temperature incubator for a period of time, pouring a mixture into the cuvette, shaking, and carrying out detection by using the pesticide residue fast detection instrument; and S5, calculating a detection result. The method has theadvantages that the preparation rate is increased, the detection speed is high, and the operation is simple.

The invention belongs to the fields of pharmaceutical chemistry and pharmacotherapeutics and discloses amide group substituted hesperetin derivatives, a preparation method thereof and an application of the derivatives as AD (Alzheimer's disease) treatment drugs. Study proves that the amide group substituted hesperetin derivatives have strong inhibition property and good inhibition selectivity on acetylcholinesterase, and inhibition capacity of the derivatives on acetylcholinesterase is more than 500 times higher than inhibitory activity on butyrylcholinesterase. The study indicates that the compounds can be developed into the AD treatment drugs.

The invention provides a multi-target tacrine derivative and a preparation method and application thereof. The compound has the structure shown in a formula (I) (please see the specification in the formula (I)), wherein n is a natural number greater than 1; m is 1 or 2; p is 0 or 1; R1 is H or halogen; and Y is selected from the following structures (please see the specification for the structures) or, a pharmaceutically acceptable salt of a compound in a formula (X). According to the compound, activity of histone deacetylase (HDACs), acetylcholinesterase (AChE) or butyryl cholinesterase (BChE) can be effectively inhibited.

The invention belongs to the technical field of medicinal chemistry and discloses a N-(1,2,3,4-tetrahydroisoquinolinyl)-feruloylagmatine-O-alkylamine compound (I) and pharmaceutically acceptable salt, and a preparation method and application thereof. The structure is as shown in a formula I. The compound (I) provided by the invention has high butyrylcholine esterase inhibiting activity, anti-oxidation activity and Abeta1-42 aggregation inhibiting activity, and has remarkable neuroprotective function on PC12 cell injury induced by hydrogen peroxide, which indicates that the compound is a multi-target-point inhibitor. The compound further shows a good effect of treating alzheimer disease in in-vivo experiments, and has low toxicity and a good clinical application prospect.

The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.

The invention belongs to the field of medicine science and technology, and particularly relates to monomer compounds having selective butyrylcholinesterase inhibitory activity obtained by performing separation from orchidaceae Bletilla striata (Thunb)Reichb.f. and medicial salt thereof, and a pharmaceutical composition containing the compounds. The 12 compounds disclosed by the invention have selective inhibitory effects on butyrylcholinesterase to different extents, and IC50 values of five of the 12 compounds are smaller than 10 micrometers, so that a powerful butyrylcholinesterase inhibitoryeffect is shown, and a unique advantage of the compounds in treatment of senile dementia diseases.

The invention provides four butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention also provides libraries comprising butyrylcholinesterase variants having at least one amino acid alteration in one or more regions of butyrylcholinesterase and further having at least one butyrylcholinesterase variant exhibiting enhanced cocaine hydrolysis activity compared to butyrylcholinesterase. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.

The invention discloses a fluorescent probe for detecting butyrylcholinesterase activity as well as a synthesis method and application of the fluorescent probe. The invention discloses a novel butyrylcholinesterase sensing strategy established on the basis of background-signal-free detection, and under the action of butyrylcholinesterase, fluorescence signals develop from nothing so that the concentration level of butyrylcholinesterase is detected. According to the fluorescent probe, a targeting site of butyrylcholinesterase is introduced into a non-emission skeleton to generate a probe P1, sothat the inherent fluorescent background of the detection probe is avoided, and the detection sensitivity is greatly improved. After butyrylcholinesterase is added, cyclopropylbutyric acid can be removed, and then spontaneous in-situ cyclization is performed to generate a fluorescent product PF to serve as an indicator for reflecting the activity of BChE. The fluorescent probe has greatly improved detection sensitivity, but also has good selectivity and biocompatibility, and has great potential in the field of clinical diagnosis.

The invention relates to a compound 1, 10-N-decylene lycorine dibromo salt showed by the structural formula (1), a pharmaceutical composition of the compound, application of the compound in the preparation of medicines for treatment of Alzheimer's diseases (senile dementia) and in the preparation of a dual inhibitor of acetylcholinesterase and butyrylcholinesterase, and preparation methods of the compound and the pharmaceutical composition.

The present application provides methods of preventing and treating the toxic effects of exposure to organophosphate agents. In embodiments, targeted cationic liposome complexes delivering nucleic acid molecules encoding butyrylcholinesterase and a polyproline rich peptide are administered. Suitably, the administration is via inhalation or via aerosol. Also provided are cationic liposome complexes and methods of making the complexes for such administration.